Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
06/10/2026 12:50
BRIEF-Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia BridgeBio Pharma, Inc. BBIO.O:
BRIDGEBIO ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF NDA FOR ORAL INFIGRATINIB FOR CHILDREN WITH ACHONDROPLASIA
BRIDGEBIO PHARMA - FDA SETS PDUFA TARGET ACTION DATE OF FEBRUARY 4, 2027 FOR ORAL INFIGRATINIB
BRIDGEBIO PHARMA - ANTICIPATES U.S. LAUNCH OF ORAL INFIGRATINIB UPON APPROVAL
BRIDGEBIO PHARMA - TO SUBMIT MAA FOR ACHONDROPLASIA TO EMA IN Q4 2026
Source text: ID:nGNX6F4nsd
Further company coverage: BBIO.O
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels